Table 2.
Immunoreactivity for FET proteins in other neurodegenerative diseases
| Diagnosis | FUS | TAF15 | EWS |
|---|---|---|---|
| AD | 0/4 | 0/4 | 0/4 |
| FTLD-TDP | 0/17 | 1/17a | 1/17a |
| FTLD with CHMP2B | 0/2 | 0/2 | 0/2 |
| FTLD-tau | 0/8 | 0/8 | 0/8 |
| ALS-TDP | 0/8 | 0/8 | 0/8 |
| ALS with SOD1 | 0/2 | 0/2 | 0/2 |
| MSA | 0/2 | 0/2 | 1/2b |
| LBD | 0/2 | 0/2 | 0/2 |
| SCA | 3/3 | 0/3 | 3/3 |
| HD | 2/2 | 0/2 | 2/2 |
| NIIBD | 1/1 | 0/1 | 0/1 |
a One FTLD-TDP subtype 2 case [according to (Mackenzie et al., 2006)] with semantic dementia showed moderated EWS-immunoreactivity in a subset of neuronal cytoplasmic inclusions in the dentate gyrus and TAF15-immunoreactivity in a small proportion of long neurites.
b One case showed EWS-immunoreactivity in a small proportion of glial cytoplasmic inclusions.
AD = Alzheimer’s disease; ALS-TDP, amyotrophic lateral sclerosis with TDP-43 pathology; ALS with SOD1 = amyotrophic lateral sclerosis due to mutations in SOD1 gene; FTLD-TDP = frontotemporal lobar degeneration with TDP-43 pathology; FTLD-tau, frontotemporal lobar degeneration with tau pathology; FTLD with CHMP2B = frontotemporal lobar degeneration with mutations in CHMP2B gene; HD = Huntington’s disease; LBD = Lewy body disease; MSA = multiple system atrophy; NIIBD = neuronal intranuclear inclusion body disease; SCA = spinocerebellar ataxia.